What is B. Riley’s Forecast for SNDX Q1 Earnings?

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) – Analysts at B. Riley issued their Q1 2025 EPS estimates for shares of Syndax Pharmaceuticals in a research report issued to clients and investors on Monday, March 3rd. B. Riley analyst K. Patel forecasts that the company will post earnings of ($1.11) per share for the quarter. The consensus estimate for Syndax Pharmaceuticals’ current full-year earnings is ($3.72) per share. B. Riley also issued estimates for Syndax Pharmaceuticals’ Q2 2025 earnings at ($1.11) EPS.

Syndax Pharmaceuticals (NASDAQ:SNDX) last announced its quarterly earnings data on Monday, March 3rd. The company reported ($1.10) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.79). The company had revenue of $7.68 million during the quarter, compared to the consensus estimate of $86.32 million.

Several other research firms also recently commented on SNDX. Scotiabank cut their price objective on shares of Syndax Pharmaceuticals from $18.00 to $16.00 and set a “sector perform” rating for the company in a report on Wednesday, January 8th. JPMorgan Chase & Co. lifted their price target on Syndax Pharmaceuticals from $35.00 to $39.00 and gave the company an “overweight” rating in a research report on Tuesday. The Goldman Sachs Group increased their price objective on Syndax Pharmaceuticals from $30.00 to $33.00 and gave the stock a “buy” rating in a report on Thursday, November 7th. Citigroup reduced their target price on Syndax Pharmaceuticals from $45.00 to $42.00 and set a “buy” rating for the company in a report on Tuesday. Finally, HC Wainwright reiterated a “buy” rating and set a $51.00 price target on shares of Syndax Pharmaceuticals in a research report on Tuesday. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $36.00.

Syndax Pharmaceuticals Stock Up 0.7 %

SNDX opened at $14.48 on Wednesday. The firm has a 50-day moving average price of $14.29 and a 200-day moving average price of $16.69. Syndax Pharmaceuticals has a twelve month low of $12.06 and a twelve month high of $25.16. The company has a market capitalization of $1.24 billion, a price-to-earnings ratio of -3.99 and a beta of 0.90.

Institutional Investors Weigh In On Syndax Pharmaceuticals

A number of institutional investors have recently made changes to their positions in the business. Polar Asset Management Partners Inc. purchased a new position in Syndax Pharmaceuticals in the 4th quarter worth $1,124,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of Syndax Pharmaceuticals by 23.8% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 170,100 shares of the company’s stock worth $2,249,000 after buying an additional 32,653 shares during the period. Voloridge Investment Management LLC bought a new stake in shares of Syndax Pharmaceuticals in the 4th quarter valued at about $1,045,000. Soleus Capital Management L.P. boosted its holdings in Syndax Pharmaceuticals by 128.4% during the 4th quarter. Soleus Capital Management L.P. now owns 2,492,000 shares of the company’s stock valued at $32,944,000 after acquiring an additional 1,401,016 shares during the period. Finally, Twinbeech Capital LP grew its position in Syndax Pharmaceuticals by 79.2% during the 4th quarter. Twinbeech Capital LP now owns 355,900 shares of the company’s stock worth $4,705,000 after acquiring an additional 157,321 shares during the last quarter.

Insiders Place Their Bets

In other news, CEO Michael A. Metzger sold 13,288 shares of the company’s stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $15.50, for a total value of $205,964.00. Following the completion of the transaction, the chief executive officer now directly owns 300,121 shares in the company, valued at approximately $4,651,875.50. This represents a 4.24 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Neil Gallagher sold 4,618 shares of the firm’s stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $15.50, for a total value of $71,579.00. Following the transaction, the insider now directly owns 85,095 shares in the company, valued at approximately $1,318,972.50. This represents a 5.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 21,683 shares of company stock valued at $336,087 in the last quarter. Corporate insiders own 4.10% of the company’s stock.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).